Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

2.

[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

Yafour N, Couturier MA, Azarnoush S, Girault S, Hermet E, Masouridi Levrat S, Schmidt A, Michallet M, Etancelin P, Guillaume T, Malard F, Sirvent A, Yakoub-Agha I, Poiré X.

Bull Cancer. 2019 Jan;106(1S):S40-S51. doi: 10.1016/j.bulcan.2018.05.018. Epub 2018 Nov 6. Review. French.

PMID:
30409466
3.

Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.

Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R.

Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25. No abstract available.

PMID:
30370957
4.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
5.

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.

Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, Etienne G, Rousselot P, Guyotat D, Janel A, Hermet E, Saugues S, Berger J, Arnaud P, Berger MG.

Mol Oncol. 2018 Jun;12(6):814-829. doi: 10.1002/1878-0261.12191. Epub 2018 Apr 27.

6.

[How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)].

Brissot E, Alsuliman T, Gruson B, Hermet E, Tirefort Y, Yakoub-Agha I, Alain S.

Bull Cancer. 2017 Dec;104(12S):S181-S187. doi: 10.1016/j.bulcan.2017.10.022. Epub 2017 Nov 21. Review. French.

PMID:
29169653
7.

Bone marrow hematons: An access point to the human hematopoietic niche.

Janel A, Berger J, Bourgne C, Lemal R, Boiret-Dupré N, Dubois-Galopin F, Déchelotte P, Bothorel C, Hermet E, Chabi S, Bay JO, Lambert C, Pereira B, Pflumio F, Haddad R, Berger MG.

Am J Hematol. 2017 Oct;92(10):1020-1031. doi: 10.1002/ajh.24830. Epub 2017 Jul 29.

8.

Prevalence of malnutrition in adult patients previously treated with allogeneic hematopoietic stem-cell transplantation.

Brotelle T, Lemal R, Cabrespine A, Combal C, Hermet E, Ravinet A, Bay JO, Bouteloup C.

Clin Nutr. 2018 Apr;37(2):739-745. doi: 10.1016/j.clnu.2017.03.016. Epub 2017 Mar 28.

PMID:
28390845
9.

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F.

Blood. 2017 May 4;129(18):2471-2478. doi: 10.1182/blood-2016-11-749556. Epub 2017 Mar 7.

10.

[Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Jaspers A, Bouhya S, Belaiche S, Chevallier P, Hermet E, Hospital-Gustems C, Michallet M, Rialland F, Samsonova O, Sirvent A, Yakoub-Agha I, Rohrlich PS, Beguin Y.

Bull Cancer. 2016 Nov;103(11S):S255-S266. doi: 10.1016/j.bulcan.2016.09.003. Epub 2016 Nov 11. French.

11.

Impact of ATG Dose on the Outcome of Patients Undergoing Reduced Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies.

Cornillon J, Balsat M, Cabrespine A, Tavernier-Tardy E, Hermet E, Mulliez A, Augeul-Meunier K, Guyotat D, Bay JO.

Acta Haematol. 2016;136(4):193-200. Epub 2016 Sep 14.

PMID:
27623172
12.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
13.

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.

PMID:
26687426
14.

Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.

Hermet E, Cabrespine A, Guièze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO; Société Française de Greffe de Moelle et de Thérapie Cellulaire.

J Geriatr Oncol. 2015 Sep;6(5):346-52. doi: 10.1016/j.jgo.2015.04.005. Epub 2015 Jun 23.

PMID:
26116168
15.
16.

Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).

Bourgne C, Janel A, Berger J, Rapatel C, Tournilhac O, Hermet E, Guerci A, Lioret F, Briançon A, Bamdad M, Boiret-Dupré N, Berger MG.

Leuk Res. 2015 Mar;39(3):329-34. doi: 10.1016/j.leukres.2014.11.014. Epub 2014 Dec 13.

PMID:
25612940
17.

Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation.

Vantyghem MC, Cornillon J, Decanter C, Defrance F, Karrouz W, Leroy C, Le Mapihan K, Couturier MA, De Berranger E, Hermet E, Maillard N, Marcais A, Francois S, Tabrizi R, Yakoub-Agha I; Société Française de Thérapie Cellulaire.

Orphanet J Rare Dis. 2014 Oct 29;9:162. doi: 10.1186/s13023-014-0162-0. Review.

18.

Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation.

Schlemmer F, Chevret S, Lorillon G, De Bazelaire C, Peffault de Latour R, Meignin V, Michallet M, Hermet E, Wyplosz B, Houdouin V, Marchand-Adam S, Socié G, Tazi A, Bergeron A.

Respir Med. 2014 Oct;108(10):1525-33. doi: 10.1016/j.rmed.2014.09.006. Epub 2014 Sep 16.

19.

[Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC].

Guillaume T, Porcheron S, Audat F, Bancillon N, Berceanu A, Charbonnier A, Dulery R, Edy N, El Cheikh J, Hermet E, Maurer N, Paul F, Konopacki-Potet J, Turlure P, Wallart A, Boulanger F, Dhédin N, Suarez F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2014 Aug;62(4):193-6. doi: 10.1016/j.patbio.2014.05.011. Epub 2014 Jul 1. French.

PMID:
24996843
20.

[Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on gonadal failure and fertility].

Cornillon J, Decanter C, Couturier MA, de Berranger E, François S, Hermet E, Maillard N, Marcais A, Tabrizi R, Vantyghem MC, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):164-7. doi: 10.1016/j.patbio.2013.07.008. Epub 2013 Sep 4. French.

PMID:
24011968
21.

[Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on dyslipidemia and thyroid disorders].

Cornillon J, Vantyghem MC, Couturier MA, de Berranger E, François S, Hermet E, Maillard N, Marcais A, Tabrizi R, Decanter C, Duléry R, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):168-70. doi: 10.1016/j.patbio.2013.07.010. Epub 2013 Sep 4. French.

PMID:
24011967
22.

[Vaccination post hematopoietic stem cell transplantation: which vaccines and when and, how to vaccinate? An SFGM-TC report].

Rubio MT, Charbonnier A, de Berranger E, Gandemer V, Magro L, Maury S, Sterkers G, Suarez F, Dalle JH, Daguindau E, Galumbrun C, Hermet É, Reman O, Turlure P, Yakoub-Agha I; French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC).

Pathol Biol (Paris). 2013 Aug;61(4):139-43. doi: 10.1016/j.patbio.2013.07.004. Epub 2013 Sep 4. French.

PMID:
24011964
23.

Enteral versus parenteral nutritional support in allogeneic haematopoietic stem-cell transplantation.

Guièze R, Lemal R, Cabrespine A, Hermet E, Tournilhac O, Combal C, Bay JO, Bouteloup C.

Clin Nutr. 2014 Jun;33(3):533-8. doi: 10.1016/j.clnu.2013.07.012. Epub 2013 Jul 31.

PMID:
23938114
24.

[Major therapeutic advances and new perspectives in onco-hematology].

Bay JO, Guièze R, Ravinet A, Lemal R, Xhaard A, Bailly S, Moluçon-Chabrot C, Hermet E, Biau J, Verrelle P, Peffault de Latour R, Tournilhac O.

Bull Cancer. 2013 Jun;100(6):587-99. doi: 10.1684/bdc.2013.1751. Review. French.

PMID:
23735575
25.

[Lymphoma and arteries: peri- or intravascular?].

Franz M, Alfidja A, Molucon Chabrot C, Hermet E, Montoriol PF, Rosset E, Boyer L, Chabrot P.

J Mal Vasc. 2013 May;38(3):162-71. doi: 10.1016/j.jmv.2013.01.008. Epub 2013 Mar 7. French.

PMID:
23473620
26.

Measurement of imatinib uptake by flow cytometry.

Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E, Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, Boiret-Dupré N, Berger MG.

Cytometry A. 2012 Nov;81(11):996-1004. doi: 10.1002/cyto.a.22118. Epub 2012 Aug 28.

27.

Prospective genotyping of human rhinoviruses in children and adults during the winter of 2009-2010.

Henquell C, Mirand A, Deusebis AL, Regagnon C, Archimbaud C, Chambon M, Bailly JL, Gourdon F, Hermet E, Dauphin JB, Labbé A, Peigue-Lafeuille H.

J Clin Virol. 2012 Apr;53(4):280-4. doi: 10.1016/j.jcv.2011.10.009. Epub 2012 Jan 21.

PMID:
22265827
28.

[Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].

Xhaard A, Hermet E, Bay JO, Peffault de Latour R.

Bull Cancer. 2011 Aug;98(8):889-99. doi: 10.1684/bdc.2011.1410. Review. French.

29.

[Therapy-related acute myeloid leukemia: role of DNA repair].

Guièze R, Ravinet A, Hermet E, Maliki Y, de Botton S, Bay JO.

Bull Cancer. 2011 Mar;98(3):247-55. doi: 10.1684/bdc.2011.1325. Review. French.

Supplemental Content

Loading ...
Support Center